Intel stock spikes after report of possible US government stake
Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton has recently reported a sale of company shares, according to a recent SEC filing. On March 17, Shelton sold 4,620 shares of Cryoport at an average price of $6.2917 per share, amounting to a total of $29,067. This transaction was made to cover taxes due upon the vesting of restricted stock rights. The sale occurred as Cryoport’s shares trade near $6.18, down nearly 59% over the past year and significantly below their 52-week high of $20.11. According to InvestingPro analysis, the stock is currently fairly valued.
In addition to the sale, Shelton also acquired 30,000 shares of common stock on March 14 as part of a restricted stock rights grant. These shares were acquired at no cost and will vest in four equal annual installments beginning March 14, 2026.
Furthermore, Shelton was granted stock options to purchase 75,000 shares at a conversion price of $7.05 per share, which will vest monthly over four years starting April 14, 2025.
These transactions reflect Shelton’s ongoing involvement in Cryoport’s equity plans as both an executive and a shareholder.
In other recent news, Cryoport Inc . reported its fourth-quarter 2024 financial results, revealing a larger-than-expected loss per share of -0.42, missing the forecast of -0.29. However, the company’s revenue exceeded expectations, reaching $59.53 million against the projected $58.64 million. Cryoport’s total annual revenues increased to $228.4 million, with a notable rise in gross margin to 45.8% from 40.6% the previous year. Looking ahead, Cryoport has set a revenue guidance of $240-$250 million for 2025, targeting positive adjusted EBITDA driven by growth in life sciences services and new product launches. Additionally, Cryoport introduced the MVE Biological Solutions’ High-Efficiency 800 C cryogenic freezer, aimed at enhancing storage capabilities for fertility clinics and labs. Analyst firm Jefferies adjusted Cryoport’s stock price target to $6.50 from $8.00, maintaining a Hold rating, and noted the company’s encouraging revenue guidance for 2025. These developments highlight Cryoport’s strategic initiatives and financial trajectory as it navigates the evolving life sciences market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.